secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001420720-24-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q3 net loss $2.6M; cash raised to $17.9M via PIPE; enters AstralBio collaboration
--------------------------------------------------------------------------------

- Net loss from continuing ops: $2.6M ($0.71/share) vs $6.3M ($9.53/share) YoY; no revenue.
- R&D expenses down 66%, G&A down 23% YoY under cash preservation strategy.
- Cash and equivalents $17.9M after $15M PIPE closed in April, up from $6.4M at March 31.
- Partnered with AstralBio to develop 4 antibody targets for obesity/cardiometabolic diseases.
- Sold early-stage PD-1 asset to Otsuka for $1M upfront and up to $52.5M in contingent payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/0001420720-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072024000018/ibio-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer